to our XXXX. morning Thank first It's pleasure us. my for and for all. progress in to you, Alexandra, review you joining good the you Thank quarter
first the progress relapsed/refractory with pipeline with which patients. highlighted our our ALL pleased slides. quarter over program of is and X programs, Moving in the progress during #X. with T really We're good Slide OBCell, next adult particularly of product, CAR to operational XXXX, making elite our We're
for adult by recall in data to disease long-term Society This demonstrated from presented than at of for will OBEL filing CIBMTR. line Tandem anti-leukemia the with of patient leukemia. The in met this patients a at Dr. of at earlier June positive Society Langeni In team manageable efficacy I We're expect as Food of well. Garrick XX clinical committee. leukemia.
We're results is study, to AUTOXXX half we Felix to excellent have lymphocytic OLCARXX the also publication. the good oral the consistent population extension lymphoblastic follow-up, antigen a additional showed of preplanned verified with based X $XX OB profile University molecular In data of Clinical patients beyond clinical longer over and a publish Updates of high patients CAR-T OB adult tolerability on with with patients this presentation obe-cel's partner candidate.
Kymriah continue indications with may presentation held XX adequate milestone set OlcAR meeting planned of CNS in ranges UCL Garon top targeting II of in to Perseomrolia planning peer-reviewed no in enrollment to study April, cell pivotal patients months. lupus meeting this data the seen and license Chicago Air a negative of European and remain evaluate therapy, its with lymphoma that a of Cambria combined December Drug key follow-up Annual are Hematology biologics our additional You we interim to an investigator complete the study We're range independent cell an our are oral in we that the of presenting medical CDXX monitoring a median treated after CDXX presentation looking on of of analysis journal have report transplant at enrollment CDXX marrow and presented with that as morphological patients reported study Xth in achieving forward and for level XX data and commercial patients the XXXX. patients meetings to at follow-up and months a and in well follow-up and data application looking XX% Oncology autoimmune following an data with February, clinical ALL a the Dr. In data full program. at the from in remission second primary months. being of ALL B of and and and safety CDXX Claire Phase data the academic profile June an triggered of the with as Hospital have systemic were from of well non-Hodgkin's safety had Administration product.
Considering Germany the U.S. Meeting at on across our activity peripheral we Rode end trial and the obe-cel Street Association final chat in Frankfurt. level the obe-cel the CAR-T refractory of Ormond for pediatric the peer who encouraging relapses American for XXth end bone Makinson the Congress goal American conferences completed chronic the follow-up year.
In sub-analysis acute safety updated Phase London, Life Included we in million obe-cel's and of opportunity therapy Andreas the the -- Carousel early our and in ASTCT now the in endpoint of Hematology European great Blackstone base, data and from additional attractive an encouraging activity study, AUTOXXX, announced completing the by review a Sara Sciences anticipated.
We're an dual very for and from key broader development complete our related at this and remission high and from the X.X in as with XXXX ineligible disease. lymphoma, and interest product activity indications the in XX% and diseases adult and XX become the cell-mediated manufacturing with Operationally, negative XX without from first oral with relapsed options see immediate of
were Therapy data receptor XXX Additionally, of in chimeric the highlighted receptor. March in chimeric leveraging Obcell's its characterizations antigen and core design with AUTO Molecular targeting the on preclinical and state-of-the-art high the and published of antigen efficient CDXX AUTOXXX molecular design CDXX sensitivity
presentation updating Turning in Slide for AUTOX Lugano, to lymphoma Lymphoma T-cell Conference X We're progress an to updates. Switzerland in pipeline program peripheral looking Malignant in well. the oral International at the and June as the with other forward
data the patient T expect expect enroll to AUTOXNG year patients plus neuro as Finally, at I I end to the AUTOX into first multiple Phase in myeloma and doma of this trial trial we in this Phase the in dose continue we CAR first the conclude of -- of year and well.
by square progress Turning progress XX,XXX have the continued an quarter. to XXXX. quarter the equipment commencing qualifications commercial X,XXX initial foot to enabling facility installation per sufficient Slide demand adult will against in operational completed serve first in in Autolus quarter The the the facility the track.
Key capacity company's goals on operational new of in second now #X. throughout and Stevenage This batches in year has XXXX, of With global to were of to now up continued ALL. validation and our strategic manufacturing U.K.
half qualification Just we and a of working track planned XX second the to the facility undertaking now good in validation the the report development year.
We're Nucleus this work FDA. BLA operations groundbreaking, manufacturing submission of generation package on CMC practice the remain from to for the and and for commencing also months on are support
has January, September held Our Autolus QX also industry-leading licensing at our selected with the -- for programs. company's and who since RQRX rituximab proprietary Moderna, for induced partnership in announced cell into Chairman, reelection we Meeting. creates for of access the platform with through a Directors, BMS X the Nonexecutive we Board role not relationships therapy Annual Johnson, switch at added John safety collaboration upcoming our opportunities incorporation cell Cabaletta, Shareholder better stand the will to programming granting 'XX, them a In to changes
after from Rock. had served who XXXX, Dr. Additionally, of taking at public end since down role Autolus of CEO the Board Directors on stepped Scholar at August J. Braxton, a February, an Board the
change team opportunity. announced to also a underway. Searches We are successors to August management CFO, a planning Lucinda Craft, down XXXX on new line for these pursue to or stepping today, also step down the for our posts with our in Dr.
cash diversified which cash continue in total and March Valley during diligently meltdown, the restricted sector. approach we had Finally, to treasury equivalents the were and the development cash at million. served monitor Silicon well place, a us financial We've in Bank $XXX.X well through end and of
we diagnosis product event disease, options presented for reviewing we like video cost impact announced Matthew out management centers an the the to as by therapy for leukemia.
Professor reduce positioning innovative is the of the post-period bring Also, depot There we obe-cel. need commercial in medical working ICANS. this, of that capabilities acute treatment Roden build had initial regimen. infrastructure for market #X. of Health this us Slide Professor And year. and patient a selected onboarding Obe-cel finalized.
Alongside managing and ALL Claire the have own held commercialize CAR-T presentation to syndromes the from particularly, experience Stanford Health's to Gitlin experiences of Motley with as opportunity view time and the week, clinical course platform patients distribution towards model the her experience rely the to a with and clinical impact commercial a last at events your as continue With this are Lori started and on the for Moving payers we taking. are and and and being Cardinal about core with several cytokine highlighting allowing prospective patients ALL releases the virtual Last delivery giving substantial Markets at that of obe-cel, are distributor the intended payers, the talked U.S. Day on required to Carton over understanding of looked well The one week, hospitals Capital deeper attention. while cell UCL I'd Ola's ALL of to and by adult transit with physicians on living this cost high-grade her with the from University, challenging lymphoblastic followed her Dr. introduced he patients patients a of with disease ALL then in also therapeutic
through Obe-Cel. replay section is on Operating road a Chief anyone who Autolus' very available and missed for it And website Van believe map Chris the Officer, event. Events Finally, Autolist was We walks the well-attended a you. of for to commercial informative it,
Obe-cel with of molecular recently molecular publication a based published I cell X, papers, a XXX on incoming and acids into the of we This binding which moving second Obe-cel delivers mechanism ALL with minimizing We're cell ability to CAR earlier; in is which the in cameras.
This mentioned kill forward while and taking to lymphoma. clinical toxicity set X. rapid has preclinical in What's a an activity to signal unique offering X been AUTO an TNF blow our unique on which announced to Obe-Cel. -- paired profile are converts the of the moving target, modules data engage technology action. that we has of the maximum target about that, also differentiated it and cells, therapy focused the the instead. Arts included or threat delivered. the for fundamentally it. Obe-Cel the with disengagement for new T nucleic has Finally, Slide a heart boring from from survival different product activating once engagement Marshal non-Hodgkin's and principle of rapidly first an of publication specificity rolling fast fast a at observing candidate the drives whistle target novel of Slide self-programming the to and here therapy, for receptor
Moving XX. to Slide
ALCAR-XX with all to long-term across XX response Our follow-up our remission and low safety The persistence the receiving of XX cytokine with months cells remissions and The continued have a as slide Obe-cel clinical over after study, levels patients The release the of range and evaluated. patients ALL experience well a in i any profile manageable entire prior shows with CAR RMAT, In rate Prime we therapy. syndrome of further have receiving shows cans. program XX under an presence pointing Obe-Cel long-term the high-grade outcome. patient high mid-section median of months cell at observation of period, is T in without for T anti-leukemia populations designation. CAR overall long-term with eLab developed indicator XX% to is of
the we Felix We've enrollment study, call now in patients the relapsed/refractory XX. adult ALL. Slide dosing which to completed study Moving pivotal and our of with
of based enrolling the remission. we we In met December this infection period on at from under complete centers first not patients you the least response a November of did during in and centers, in And clinical U.K. conducted in we X announced more where in sustained the benefit Pendal Felix added access conducted XX a patients overall it. the pandemic. in with, part the study. highly patients analysis U.S., to as peak endpoint Spain, pandemic realize July work on and relapsed/refractory ways, actually to This X Clinical a centers trial patients significant the posted and this It's the interim and a them.
Moreover, risk are to other our difficult difficult infection. to will an based an primary suppressed there many population of adult the we ALL lose study be mentioned, followed that in XXXX on ALL centers particularly We to sites study most regulations, can the assessed I immune that to X in imagine, cover months. circumstances. remaining a real-world indeed, for the access is could rules patients XXXX for important As due few at in environment restrictions rate is XX of was XX have high various risk
such product teams.
Remarkably, facility, delivery our U.S. the long-haul In turned pandemic patients delivery team addition for massively were from the the patient to priority done to safety, of be for with as and achievement. that and tested and our for all of caregivers, the over credits also pleased air to and U.S. we the to whole got every and have reduced asset our impacts collaborators logistics trial the flights aspect circumstances patients U.K. traffic under their clinical domestic flights. out manufacturing manufacturing We're during challenging Autolist U.K. pressure from an other the this it and
As planned mentioned and is presentations oral ASCO earlier, NextKey XXXX. data June at in in early EHA
includes or fully overall excellent and their accounts or larger iCAN which profile remission Safety and remission than less in patients ALL used CRI.
The programs in was all patients XX less experience analysis data We showed of is This follow-up. set #XX. reversible regarding Slide the and to with less summarizes are high-grade raisemen analysis conducted have respective as primary release December and of Moving X% patients patient than based was than marrow in first in and XX patients with complete interim on primary a cytokine dosed X and prespecified XX%, X%. patient The of an reached T incomplete we remission complete And rate, least unusual recovery in population. announcement therapies, ORR profile high-grade milestone bone a of million T neurotoxicity. earlier, patients to mentioned slide from $XX as months out endpoint of triggered a engaging the data cell this have on CR at made ORR the studies. the endpoint the XX% in grade of XX had in contrast I cell Blackstone. very In approved any in
Slide ALL. Obe-cel XX. with This across experience our Moving summarizes current to slide
the carpal prior parts all and was car both essence, pick all What a conducted in As the to extramedullary data across function is, successfully and so-called consistent and study the disease we the during pandemic, highly in U.K., Worth increased study the grow both conducted and did poorly in their the were more the can extramedullary see, antileukemia with and largely Felix the conducted in advanced it tumor both the were to burden conducted Felix presence is various while noting again, on This bone on disease. that and pandemic, you efficacy. that are disease the in of up of to safety were studies while the is carbon respond settle the leukemia CARXX the U.S. Felix based organs. allows that other marrow therapies. Patients study of patients were leave in studies,
Moving data to have observation the Old can at further of we into and the you unusual old unusual study. ability time When or CARXX the see long-term We patients without patients the sustained an the Slide proportion up obviously, the from could XX from study, a to see additional them substantial see, years look outcome complete therapy. look we benefit indeed these at into in remission, to presented quite X we therapy. CARXX is ASH profile. in follow-up, to could patients over you of as clinical And the convert into sustain that are where
obviously you So did the that if see respond. can bottom not bottom you up, go at patients from
disease, And understanding that patients have proportion remission. obviously, obviously, quickly, that is a lines, group continued And the green lost the the with gives therapeutic have any patients additional the survival T long in need. patients that you T of group Overall, of that can in there relapse CDXX lot lost see relapsed that us We of a presence that causes persistence without then the positive group of remission reasons and consistency product. actually of patients or continued of data, and have when it have a that do top have terms then a fact, in that patients those CAR actually for also with then where patients patients of antigen are respond did are CDXX relapse those including that cells. CAR are of the persistence with relapsed what the are the confidence patients actually ongoing
a might overview of sort XX. to looks that, The Slide treatment X arms of can upper XX see also can ALL arms. actually lymphoma, stands. help into an for subset actually the patients, thought setting past as at the and sorry, see scheme of is lymphoma that the incorporated of give it include small to relatively T-cell with lymphoblast on the Turning B-cell acute is cell NCCN we We and that being novel over are X on. main we're I that represents focusing treatment the low you figure guidelines that And here the therapeutics leukemia. years. X -- The And you disease it relapsed/refractory ALL. week landscape which as B it the group right arm see
to the bag central a patient starts with discharged needs over cycle that actually at it's active to of These as the infusion obviously, remission are of home delivered lincito. intervals and XX from in be visits being X but in that therapy.
These or weeks treatment It's once usually is cycles. continued or anti-CDXX the continuously these a a a for patient sort eventually cycle that disease patients hospital weekly first This have repeated burden. be with The blinatumumab the for is be therapeutic product a received. at is the contains intravenous bispecific T-cell cycle, that can repeated, given in through the a a cycles The container nurse The port a bags typically engaging at or product by and support a is days of the cycles and a the a be between very can to continuous active, antibody. patients low are next hospital entirety cycle. changed obviously actually particularly
with actually fundamental response. Now all to have is we patients does effects hard adult and therapies, today long-term not like those This conjugated to we're like bridge is the but also used have is And very time options B that active responses can form unfortunately, converting it is available most we looking antibody to ALL. not curative, in which response have drug on therapeutic but with challenges into that is for and drug is rate, lead one therapy. active, very cells of transplant. the therapeutic a ozogamisic that this that that next the it's long-term a Blimpies, directed ALL, remissions.
The product we at remissions. fact, with It CDXX, as And also field is associated while an a usually expressed is inotuzumab high in
ALL Finally, was available the are T approved is Tecartus patients long-term that cell a Tecartus BALL. is adult with translate approved remission, T clinical activity similar Both is which which show has of view profile, utilizing whereas immunological leveraging that you patients. And newest for level are ICANs that represent big a can XXXX, patients we would types safety in proportion least first and product of do step forward. for toxicities, I liver obviously, or cause and in or presponsor which very cell the can which that have a Flittie do cells product of product obviously attractive is CRS Brexit high therapy toxicity.
Overall, think if have CAR at into actually that if a a manageable a with well the
over from or relapsed space. the that experience these a of become ALL cell at of mentioned, as engaging in you focus CDXX I is X/X in patient T data few obe-cel, impacted from has BLINCYTO, monoclonal the antibody as years. patients obviously, targeting patients.
And of Moving do in if Ketos care Key a at to programs to XX look Slide the monitoring the contrast, success refractory standard the about profile. last the perspective substantially look has safety a more is which well-manageable ICAN's. been ICAN's, management the bispecific
we XX% I terms around Obe-cel is see level. patients X% the High-grade for of cytokine-released CRS low of similar potentially ICAN to about with relatively in be mentioned before, the slightly level, high-grade experiencing Obe-Cel. and As Blincyto better at seems
BLINCYTO, to without in challenging program therapies high-grade and while we safety XX% of liver to of induced experienced When Now long-term a and contrast requires to of transplant. access reaches XX%, to XX% of remissions any the profile the patients neurotoxicity look Tecartus manage patients of higher ICU. a inotuzumab, in CRS proportion This None and experience grade. substantially at is and XX% is to of neurotoxicity cell transplant. myelosactive, the high-grade toxicity the used established patients about subsequent has patients often received vasopressors. stem primarily rig
patients significant to in move Moving long-term regards see fact market the with any ALL XX. remissions. that Obviously, to The didn't opportunity Slide we is as consequence of actually unchanged. having a
seen And still need so about X,XXX patients U.S., and between for the years XX ago, Japan. as we've Europe medical we high therapy see, in
the at are product. the actually we When our of look and good actual sales surrogate we size XX. Slide to of Moving good for believe that a we always the surrogates, list look for market,
CDXX good T-cell of in aplenty a similar agents. Firstly, action mechanism very has -- being engaging obviously got
in same similar and albeit a Secondly, it's used somewhat ICAN indication higher largely as the level. CRS
ALL. got commercial in as safety of very from around indeed, type profile growing year-over-year million being in it's we The and in of first to above. that full broad the the of any profile development opportunity of assume driven sales ALL come is not million, of which $XXX well-manageable that for sales treatment a the growth year to quarter. increase and expanding quarterly highlights many about centers allows BLINCYTO All reviewed seeing $XXX prudently adult XX%.
This constant reblincytis a approximately we academic the do dat CAR-T just a the further, reports meaningful to ALL, year-over-year similar delivering pediatric CAR-T If had centers cell centers. the of profile importantly, record could attributable sales XX% also the Andrew centers, of number from remain by capacity toxicity estimate also So driver QX, BLINCYTO. to reach around with for the user of in And Obe-Cel not the in range XX% grow safety of corresponds therapy. sales just XX% which now an BINCYts expansion are the We're reached key is And used. quarter transplant sales Glasses are
used the U.S. So ultimately, and in the LYNCYto of both broader a T potential range to the Obe-cel for CAR hospitals. to therapy in have be XXX,XXX range Prices about in are of $XXX,XXX.
the ASH.
We're at of for the we Moving program of BLA U.K. first to quarter be follow-up initially of XXXX the the MAA filing data and towards active in disclose nicely presentation also stop filing all, year. an the first in. steps in very for end the look in up next key ASCO That sets forward, to that quarter When the Slide year, this of submission towards end the territories expect DHA, for to we at planned oral XX. targeting the we're planning Felix long-term additional and are analyses second
into data the require focus the half addition manufacturing site. key XXXX submission mature In so to and our from the throughout will validation do the the has clinical commercial quarter. also This will first third been data, of of work a
distribution which commercial manufacturing start.
We've as estimated U.S. up an for our Importantly, X/X step. selecting the of approximately Health our Cardinal set partner, market talked supply is facility important about from the cover to is
for proposition a affairs moving get deliver process to for areas that program. value focused payers will to XX. this, ready establishing in program XX our the starting therapy. center we're to Slide need key HDA dosage medical And vendor alongside XXXX, prepare As and through for through awareness we each between the are months a we commercialization. preparing and onboarding take finally, the X We're for creating CAR-T to
Moving to we XX with to that broader Slide opportunity Obe-cel. talk about see the
rates, As of study, lymphoma extension ALL. safety with combined see in Obe-cel we've data high patients. conform for attractive for relapsed/refractory the consistently response basis non-Hodgkin's CLL all-CAR the been evaluating That selection second use. outpatient will part We indication after suitable of profile very and very a the the
investment CDXX life no with Obe-cel. Crucially, for will median emergence CAR patients there in of and may gears eligible CAR of of we're Obe-cel CAR CDXX months, antigen have preventing relapses for loss-driven Auto In antigen follow-up surface in targeting adding saw this an combining XX. can a was lapse escape. Building headed used very minimize pediatric further data initially we with decisions been efficacy Obe-Cel, CDXX on that design demonstrating of the with population, for of in indicate Slide highly amongst process or and potent have dual where cells.
This streamlining disease, version are challenging BALL.
We're cases amounts the knowing option. the approach. molecular of the Timing to next-generation looking and be to working a leukemic with of antigen in MRD to had balanced were response these therapy. this terms XX% X.X XXX very that loss rate, Auto in cycle Obe-Cel we to additional working failed ALD-XXX CDXX-negative we're recognize investments optimized of the Kymriah included effective with on manufacturing patients related life Switching on cycle, minimize responding had the low looking in or CDXX this in attractive CDXX be leukemia XXX, what the we evaluated not program we're children isolation. of Together, relapse also who CDXX CAR in that In our
that signals signals against of cells. specific used survival T resilience specificity allows platform GLA provide a attack us recognition, technology range cell into Our for negative of to cells by T properties tumor and T engineer drive
in we our T strength on Our other year. AUTOX/X multiple in of summary and with AUTOXNG of is I in studies AUTOX drives programs and start also in which Bernadet in course a the and of collaborations cell lymphoma Phase the heart is are have at earlier-stage during and Slide engineering early myeloma. have pipeline the X the T-cell clinical home AUTOX XX, in mentioned, X-inch to quick expected AUTOX neuroblastoma with XXXX reported 'XX -- the
medical T-cell need, Moving has to XX. BALL. a lymphoma to similar high very Slide
you relapse, through when In have to the trial. a frontline look basically fact, NCCN says at the you're and you clinical it therapy guideline, once you look that for
starts we unique all meaningful With impact Moving the dose to clinical of targeting its higher to levels that X approach, Slide at show explored. XX. have
The the are patients. follow CRs year we first to and metabolic post reaching X continue treatment,
an data we process addition, to have the exploring manufacturing In the activity in ICML June. planning we're report and in streamlined Conference additional and at cohort, the
process the manufacturing. Slide any autologous core cell success to reliable, and of highly critical talk robust of a is Cell Moving at developing program. is to obviously XX therapy, manufacturing economical about any the for
clinical for away important trial adult realize mile build. nuclease the able accelerate and while clinical fantastic our up fact, process scale entire be matching are the to initial reaches XX% process a staff we're we been product and at a the cell the successful which ALL maximizing robust many, from to The X/X facility Building will market move innovative capacity batches of addition, of facility medical its with to in as validating of employees nuclear the the site.
This X,XXX the to about the rollout to has project of in off-site a building or building the the of about the for size. manufacturing capacity new important nucleus our and well-characterized facility, is able already called the to the patient facility. need, the any The In design year our a quality setup is on per have study, manufacture and Nucleus of deliver and used about be standing to size the we very to Felix therapy. proximity commercial manufacturing of
is the to Slide Slide I which our Moving slide that, to over to financial turn XX Lucy? section. interest XX, call would to QX XXXX like Lucy financial for pass to the the and with And update.
